1
|
Beswick DM, Kaushik A, Beinart D, McGarry S, Yew MK, Kennedy BF, Maria PLS. Biomedical device innovation methodology: applications in biophotonics. JOURNAL OF BIOMEDICAL OPTICS 2017; 23:1-7. [PMID: 29243414 DOI: 10.1117/1.jbo.23.2.021102] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/11/2017] [Accepted: 11/15/2017] [Indexed: 05/03/2023]
Abstract
The process of medical device innovation involves an iterative method that focuses on designing innovative, device-oriented solutions that address unmet clinical needs. This process has been applied to the field of biophotonics with many notable successes. Device innovation begins with identifying an unmet clinical need and evaluating this need through a variety of lenses, including currently existing solutions for the need, stakeholders who are interested in the need, and the market that will support an innovative solution. Only once the clinical need is understood in detail can the invention process begin. The ideation phase often involves multiple levels of brainstorming and prototyping with the aim of addressing technical and clinical questions early and in a cost-efficient manner. Once potential solutions are found, they are tested against a number of known translational factors, including intellectual property, regulatory, and reimbursement landscapes. Only when the solution matches the clinical need, the next phase of building a "to market" strategy should begin. Most aspects of the innovation process can be conducted relatively quickly and without significant capital expense. This white paper focuses on key points of the medical device innovation method and how the field of biophotonics has been applied within this framework to generate clinical and commercial success.
Collapse
Affiliation(s)
- Daniel M Beswick
- Stanford University, Department of Otolaryngology, Head and Neck Surgery, Stanford, California, United States
- Oregon Health and Science University, Department of Otolaryngology, Head and Neck Surgery, Portland,, United States
| | - Arjun Kaushik
- SPARK Co-Lab, Perth, Western Australia, Australia
- Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
| | - Dylan Beinart
- SPARK Co-Lab, Perth, Western Australia, Australia
- Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
| | - Sarah McGarry
- SPARK Co-Lab, Perth, Western Australia, Australia
- Curtin University, School of Occupational Therapy and Social Work, Faculty of Health Sciences, Bentl, Australia
| | - Ming Khoon Yew
- SPARK Co-Lab, Perth, Western Australia, Australia
- Royal Perth Hospital, Department of General Surgery, Perth, Western Australia, Australia
| | - Brendan F Kennedy
- QEII Medical Centre, Harry Perkins Institute of Medical Research, BRITElab, Nedlands, Western Austra, Australia
- University of Western Australia, Centre for Medical Research, Perth, Western Australia, Australia
- University of Western Australia, School of Electrical, Electronic and Computer Engineering, Perth, W, Australia
| | - Peter Luke Santa Maria
- Stanford University, Department of Otolaryngology, Head and Neck Surgery, Stanford, California, United States
- SPARK Co-Lab, Perth, Western Australia, Australia
- University of Western Australia, Department of Ear Sciences, Perth, Western Australia, Australia
| |
Collapse
|
2
|
Vasaikar S, Bhatia P, Bhatia PG, Chu Yaiw K. Complementary Approaches to Existing Target Based Drug Discovery for Identifying Novel Drug Targets. Biomedicines 2016; 4:E27. [PMID: 28536394 PMCID: PMC5344266 DOI: 10.3390/biomedicines4040027] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2016] [Revised: 11/16/2016] [Accepted: 11/17/2016] [Indexed: 02/07/2023] Open
Abstract
In the past decade, it was observed that the relationship between the emerging New Molecular Entities and the quantum of R&D investment has not been favorable. There might be numerous reasons but few studies stress the introduction of target based drug discovery approach as one of the factors. Although a number of drugs have been developed with an emphasis on a single protein target, yet identification of valid target is complex. The approach focuses on an in vitro single target, which overlooks the complexity of cell and makes process of validation drug targets uncertain. Thus, it is imperative to search for alternatives rather than looking at success stories of target-based drug discovery. It would be beneficial if the drugs were developed to target multiple components. New approaches like reverse engineering and translational research need to take into account both system and target-based approach. This review evaluates the strengths and limitations of known drug discovery approaches and proposes alternative approaches for increasing efficiency against treatment.
Collapse
Affiliation(s)
- Suhas Vasaikar
- Integrative Biology, Baylor College of Medicine, Houston, TX 77030, USA.
| | - Pooja Bhatia
- School of Biological Sciences, Indian Institute of Technology, Delhi 110016, India.
| | - Partap G Bhatia
- Department of Pharmaceutics and Pharmaceutical Microbiology, Usmanu Danfodiyo University, Sokoto 840231, Nigeria.
| | - Koon Chu Yaiw
- Experimental Cardiovascular Research Unit, Department of Medicine-Solna, Center for Molecular Medicine, Karolinska Institute, Stockholm 17177, Sweden.
| |
Collapse
|